Home › Employers › Glendive Medical Center
Glendive Medical Center: H-1B salaries and sponsorship
Glendive Medical Center filed 4 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 4. Median offered salary: $67,600.
Does Glendive Medical Center sponsor H-1B visas?
Glendive Medical Center filed 4 labor condition applications in fiscal years 2023–2026, the latest submitted on Dec 14, 2023. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Medical Laboratory Technologist | 4 | $67,600 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2023 | 2 | $67,600 |
| FY2025 | 2 | $67,600 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Medical Laboratory Technologist | $62,400 Level II | Glendive, MT | Dec 14, 2023 | Mar 15, 2024 | Certified, then withdrawn |
| Medical Laboratory Technologist | $72,800 Level II | Glendive, MT | Dec 14, 2023 | Mar 15, 2024 | Certified, then withdrawn |
| Medical Laboratory Technologist | $62,400 Level II | Glendive, MT | Dec 7, 2022 | Mar 15, 2023 | Certified |
| Medical Laboratory Technologist | $72,800 Level II | Glendive, MT | Dec 7, 2022 | Mar 15, 2023 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).